Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Dmh3.0

DMHA (Octodrin) – Forschung

Überwiegend Mechanismus / Beobachtung

5 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu DMHA (Octodrin) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus gemischt-qualitativen Studien, veröffentlicht 1967–2021.

Basierend auf 5 Studien

Konfidenz

Geringe Konfidenz

Nach Outcome

Safety, regulation & detection
Überwiegend Mechanismus / Beobachtung5 Studien
Cardiovascular & sympathomimetic risk
Überwiegend Mechanismus / Beobachtung4 Studien
Metabolic / weight-loss claims
Überwiegend Mechanismus / Beobachtung3 Studien

Stetige Forschung

1 Studie in den letzten 5 Jahren

196719942021

1Beobachtungsstudie2021

Einfach gesagt: These cocktails of stimulants have never been tested in humans and their safety is unknown.

Cohen PA, Travis JC, Vanhee C, Ohana D, Venhuis BJ · Clinical toxicology (Philadelphia, Pa.) (2021)

Multi-laboratory survey of US weight-loss and sports supplements found nine prohibited stimulants, including octodrine (DMHA) at 18–73 mg per serving
Many products stacked multiple stimulants — up to four experimental stimulants in a single product
Explicitly concludes the stimulant cocktails have never been tested in humans and their safety is unknown

Quelle ansehen

2Beobachtungsstudie2018

Einfach gesagt: Octodrine was found at a dose (±95% CI) of 72 ± 7.5 mg per serving ... The quantity of octodrine found in our study was more than twice the largest pharmaceutical dose.

Cohen PA, Travis JC, Keizers PHJ, Deuster P, Venhuis BJ · Clinical toxicology (Philadelphia, Pa.) (2018)

Analytical study designed to find a new 1,3-DMAA-like stimulant in US supplements after the FDA banned DMAA — and it found octodrine (2-amino-6-methylheptane / DMHA)
Octodrine was present at ~72 mg per serving — more than twice the largest historical European pharmaceutical dose (8–33 mg)
Products also contained the analog 1,4-DMAA and the banned stimulants 1,3-DMAA and 1,3-DMBA, with 1,3-DMAA linked to hemorrhagic stroke and sudden death

Quelle ansehen

3Übersicht2018

Einfach gesagt: Octodrine is the trade name for Dimethylhexylamine (DMHA), a central nervous stimulant that increases the uptake of dopamine and noradrenaline ... Reported side-effects include hypertension, dyspnoea and hyperthermia.

Catalani V, Prilutskaya M, Al-Imam A, Marrinan S, Elgharably Y, Zloh M, et al. · Brain sciences (2018)

First pharmacology-focused review of octodrine/DMHA in seven decades — characterizes it as a CNS stimulant increasing dopamine and noradrenaline uptake, originally a 1950s nasal decongestant
Only five relevant scientific publications existed; most user information came from bodybuilding fora marketing it as 'the god of stimulants'
Reported harms include hypertension, dyspnoea, and hyperthermia, with concern about athlete safety and doping

Quelle ansehen

4In vitro2018

Einfach gesagt: Fifteen Aconitum or Kigelia plant samples ... none of them contained 1,5-DMHA ... the enantiomeric distribution and the presence of the synthetic byproducts all suggested the synthetic origin of 1,5-DMHA in the commercial products.

Wang M, Haider S, Chittiboyina AG, Parcher JF, Khan IA · Journal of pharmaceutical and biomedical analysis (2018)

Counter-evidence to the marketing claim that DMHA is a 'natural' constituent of Aconitum or Kigelia plants — none of 15 plant samples contained it within the detection limit
DMHA in supplements was racemic and carried synthesis byproducts, indicating a synthetic, poor-quality source rather than a botanical extract
One product contained up to 112 mg per serving — over three times the highest European pharmaceutical dose

Quelle ansehen

5Tierstudie1967

Einfach gesagt: Pharmacology of the octodrine salt 2-amino-6-methylheptane-(+)-camphor-10-sulfonate.

Oelkers HA · Arzneimittel-Forschung (1967)

Historical (1967) pharmacology of octodrine (2-amino-6-methylheptane), from the era when it was used as a pharmaceutical pressor/sympathomimetic
Documents the sympathomimetic/circulatory pharmacology that underlies its stimulant and pressor effects
Predates the supplement era by decades — confirms octodrine is an old drug, not a novel dietary ingredient

In der Forschungsbibliothek ansehen

DMHA (Octodrin) – Forschung

Überwiegend Mechanismus / Beobachtung

Nine prohibited stimulants found in sports and weight loss supplements: deterenol, phenpromethamine (Vonedrine), oxilofrine, octodrine, beta-methylphenylethylamine (BMPEA), 1,3-dimethylamylamine (1,3-DMAA), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylbutylamine (1,3-DMBA) and higenamine.

Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA).

Octodrine: New Questions and Challenges in Sport Supplements.

1,5-Dimethylhexylamine (octodrine) in sports and weight loss supplements: Natural constituent or synthetic chemical?

[On the pharmacology of 2-amino-6-methylheptane-(+)-camphor-10-sulfonate].